Skip to main content
SICHUAN BIOKIN PHARMACEUTICAL CO., LTD. logo

SICHUAN BIOKIN PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 688506 ISIN · CNE100006FN4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 516 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688506

About SICHUAN BIOKIN PHARMACEUTICAL CO., LTD.

http://en.baili-pharm.com/

Sichuan Biokin Pharmaceutical Co., Ltd. focuses on the research, development, and commercialization of innovative therapeutic agents, with a primary emphasis on oncology. The company leverages proprietary technology platforms to engineer multi-specific antibodies and antibody-drug conjugates (ADCs). Its R&D strategy targets complex disease mechanisms through the development of bispecific, trispecific, and tetra-specific antibody therapies designed to modulate immune responses and deliver cytotoxic payloads with high precision. Biokin maintains an integrated infrastructure encompassing drug discovery, preclinical evaluation, clinical trial management, and GMP-compliant manufacturing. The pipeline includes several first-in-class and best-in-class candidates aimed at treating various solid tumors and hematological cancers. By integrating advanced molecular engineering with comprehensive clinical development capabilities, the company aims to provide novel treatment options for patients globally.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于四川百利天恒药业股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 85% confidence The document is a continuous supervision follow‐up report (“持续督导跟踪报告”) issued by the listing sponsor (中信证券) under Chinese securities rules. It is not an earnings release or financial statement (IR/10‐K) but rather a compliance/regulatory report on ongoing sponsor duties, containing findings, risk disclosures, and detailed review procedures. It does not fit any specific category such as annual report, audit report, M&A, or director dealings, so it defaults to a general regulatory filing.
2026-05-21 Chinese
中信证券股份有限公司关于四川百利天恒药业股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings Classification · 75% confidence The document is a sponsor’s on-site inspection report under continuing supervision guidelines (“持续督导工作现场检查报告”) for a listed company, detailing compliance with governance, disclosure, fundraising usage, related party transactions, etc., and is not an annual or periodic financial report, earnings release, audit report by an auditor, nor any other specific category. It is a regulatory compliance filing and falls under the fallback category “Regulatory Filings” (RNS).
2026-05-21 Chinese
北京君合（成都）律师事务所关于四川百利天恒药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 93% confidence The document is a legal opinion letter (‘法律意见书’) from outside counsel regarding the convening, attendance, and voting procedures and results of the 2025 annual shareholders’ meeting. It does not itself contain financial statements, proxy materials, or voting results for direct publication, nor is it an earnings release, interim or annual report, or investor presentation. It is an attestation/certification by lawyers concerning compliance with laws and corporate bylaws. Under the Certification Rule and fallback guidelines, such letters are treated as general compliance or regulatory filings. Therefore, the document should be classified as Regulatory Filings (RNS).
2026-05-19 Chinese
四川百利天恒药业股份有限公司关于董事长代行董事会秘书职责的公告
Board/Management Information Classification · 85% confidence The document is an official announcement by the company regarding changes in the board/management (specifically the acting duties of the board secretary). It does not contain financial data or constitute an annual or interim report, earnings release, or other filing types such as legal proceedings. It clearly fits the definition of "Board/Management Information" (changes in board or senior management duties).
2026-05-12 Chinese
四川百利天恒药业股份有限公司自愿披露关于iza-bren（EGFR×HER3双抗ADC）联合用药治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement disclosing receipt of a clinical trial approval notice from China’s National Medical Products Administration for its drug candidate. It involves regulatory approval information rather than financial results, capital activities, management changes, or formal report attachments. It does not contain full financial statements or in-depth analysis. This fits best as a general regulatory filing announcement (RNS).
2026-05-12 Chinese
四川百利天恒药业股份有限公司2025年年度股东会会议资料
AGM Information Classification · 98% confidence The document is titled “2025年年度股东会会议资料” (2025 Annual General Meeting materials) and contains detailed AGM notices, agenda items, proposals, attachments (e.g., board work report, profit distribution, annual report summary), and procedural rules for the shareholders’ meeting. This matches the definition of materials presented during an Annual General Meeting (AGM Information).
2026-05-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.